e-ISSN: Pending
Negative / Null Result ReportOpen accessTherapeutics. Pharmacology

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients

Kun Wang; Yuanyuan Shen; Chen Hu; Fengyan Xu; Qingyu Wang; Yuying Gao; Liang Zhou · 2025 · Clinical and Translational Science

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

ABSTRACT While PD‐L1 antibodies have demonstrated efficacy in small cell lung cancer, the therapeutic benefits remain limited. To address this unmet medical need, serplulimab was developed as an innovative monoclonal antibody targeting PD‐1. This study evaluated the pharmacokinetic (PK) properties of serplulimab and their relationship with efficacy and safety in patients with extensive‐stage small cell lung cancer (ES‐SCLC), using population pharmacokinetics (PopPK) and exposure–response (E–R) analysis to inform dose selection. Data from 1144 patients across eight Phase I–III clinical trials s

Abstract by Kun Wang; Yuanyuan Shen; Chen Hu; Fengyan Xu; Qingyu Wang; Yuying Gao; Liang Zhou, Clinical and Translational Science (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1111/cts.70322